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ABSTRACT
Objectives: Stratified medicine is often heralded as
the future of clinical practice. Key part of stratified
medicine is the use of predictive biomarkers, which
identify patient subgroups most likely to benefit (or
least likely to experience harm) from an intervention.
We investigated how many and what predictive
biomarkers are currently included in European
Medicines Agency (EMA) licensing.
Setting: EMA licensing.
Participants: Indications and contraindications of all
drugs considered by the EMA and published in 883
European Public Assessment Reports and Pending
Decisions.
Primary and secondary outcome measures: Data
were collected on: the type of the biomarker, whether it
selected a subgroup of patients based on efficacy or
toxicity, therapeutic area, marketing status, date of
licensing decision, date of inclusion of the biomarker
in the indication or contraindication and on orphan
designation.
Results: 49 biomarker–indication–drug (B-I-D)
combinations were identified over 16 years, which
included 37 biomarkers and 41 different drugs. All
identified biomarkers were molecular. Six drugs
(relating to 10 B-I-D combinations) had an orphan
designation at the time of licensing. The identified B-I-
D combinations were mainly used in cancer and HIV
treatment, and also in hepatitis C and three other
indications (cystic fibrosis, hyperlipoproteinaemia type
I and methemoglobinaemia). In 45 B-I-D combinations,
biomarkers were used as predictive of drug efficacy
and in four of drug toxicity. It appeared that there was
an increase in the number of B-I-D combinations
introduced each year; however, the numbers were too
small to identify any trends.
Conclusions: Given the large body of literature
documenting research into potential predictive
biomarkers and extensive investment into stratified
medicine, we identified relatively few predictive
biomarkers included in licensing. These were also
limited to a small number of clinical areas. This might
suggest a need for improvement in methods of
translation from laboratory findings to clinical practice.
INTRODUCTION
Drugs are rarely effective in all patients and
may be associated with serious adverse events.1
The challenge of stratiﬁed medicine is to iden-
tify predictive biomarkers that identify patient
subgroups (or strata) with a differential thera-
peutic response to a linked intervention, allow-
ing more appropriate and effective use of
interventions to maximise patient beneﬁt and
minimise the occurrence of serious adverse
events.2 3 Predictive biomarkers are deﬁned
particularly to a treatment for a condition,
where biomarker values are associated with dif-
ferential efﬁcacy or toxicity of that treatment.4–7
The use of predictive biomarkers promises a
more appropriate choice of treatment; it can
also help to rationalise funding decisions, avoid-
ing costs of futile treatment and of adverse
events. However, the additional cost of measur-
ing the marker has to be taken into account.
Examples of predictive biomarkers include tam-
oxifen use in breast cancer, which is prescribed
to women who are oestrogen receptor positive,8
and trastuzumab, which is prescribed to those
with HER2 overexpression in their tumour.9
There is a large body of literature docu-
menting research into potential predictive
biomarkers,10 11 and millions of pounds have
Strengths and limitations of this study
▪ Our research, to our knowledge, provides the first
indication of the number and nature of predictive
biomarkers included in licensing in Europe.
▪ We used systematic review methodology.
▪ It is likely that the 49 identified biomarker–indi-
cation–drug combinations do not represent a
complete list of predictive biomarkers used in
practice, as some could have been considered by
national regulatory agencies, particularly for
drugs considered before European Medicines
Agency was established in 1995.
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been invested into stratiﬁed medicine, in industry and
through programmes from funding bodies such as the
Medical Research Council12 and Cancer Research UK.13
We aimed to investigate whether this interest in develop-
ing stratiﬁed medicines has led to production of
biomarker-treatment combinations ready for use in clin-
ical practice. To explore this question, we have under-
taken a systematic review of predictive biomarkers
reported in licensing decisions of the European
Medicines Agency (EMA).
In our review, we aimed to ﬁnd out how many of the
indications and contraindications considered by the
EMA deﬁne a patient population using a predictive bio-
marker. We were also interested in the disease areas
where predictive biomarkers have been used and any
trend over time. It has been hypothesised that stratiﬁed
medicine has not been implemented in practice as
much as expected. This paper provides evidence of the
impact of stratiﬁed medicine research to date and if less
than expected, then this will highlight the need to
review the underlying reasons and address the problems.
METHODS
We deﬁned a biomarker–indication–drug (B-I-D) com-
bination as the unit of our analysis, relating to the use of
a predictive biomarker with a particular drug for a par-
ticular condition or disease.4–7 For toxicity biomarkers
where biomarkers of drug toxicity may be used in more
than one disease area we grouped these into one B-I-D
combination.
All drugs listed on the EMA website in either
European Public Assessment Reports or Pending
Decisions14 15 (accessed on 17 January 2013) were evalu-
ated, together with their indications and
contraindications.
Our inclusion criteria were that the biomarker had to
1. Be used in the indication and/or contraindication of
a drug;
2. Be associated with a particular treatment;
3. Identify a subgroup of patients with a particular
disease eligible for treatment with the drug.
We excluded biomarkers
1. Associated with a non-therapeutic substance (eg,
vaccines).
2. Not used as predictive, including:
A. Used for diagnosis, screening or forming part
of the disease deﬁnition (already established
for deﬁning a disease) or established disease
subtype;
B. Prognostic only (associated with outcome
regardless of treatment and not predictive of
treatment response16).
3. Associated with another treatment (eg, the bio-
marker was not associated with the differential efﬁ-
cacy or toxicity of the drug of interest, but another
drug given in combination with the drug of interest).
We have reviewed EMA licensing, as in Europe, a centra-
lised drug evaluation by the EMA is required for drugs
used in the treatment of a number of conditions, drugs
obtained from biotechnology processes and all drugs used
for rare conditions (orphan medicines). Companies can
also apply for a centralised marketing authorisation of
other drugs.17 Although the EMA does not license biomar-
kers, it evaluates drugs in groups deﬁned by predictive bio-
markers (eg, trastuzumab is licensed for use in HER2
overexpressing patients with breast cancer).18 Our
approach is likely to give a broad overview of the impact of
predictive biomarkers on treatment selection since 1995
(when EMAwas established19).
We created a database of all drugs in the EMA data-
base including the drug name, licensing status, indica-
tion and contraindication. In the ﬁrst stage of screening,
all database entries were screened by two independent
reviewers (MB and KM) to identify those potentially
including a predictive biomarker in the indication or
contraindication. If an entry was identiﬁed by at least
one of the reviewers as potentially relevant, it was
included in the second stage of screening.
In the second stage of screening, a list of potential
B-I-D combinations was created based on the entries
identiﬁed in the ﬁrst stage. The list of potential B-I-D
combinations was assessed by two independent reviewers
(MB and KM) using full inclusion/exclusion criteria,
based on the information in the Summary of Product
Characteristics (which sets out the position of the drug
obtained in the assessment process and summarises its
properties and clinical use together with the clinical
trial evidence that was considered by the EMA),20 the
Scientiﬁc Discussion (which discusses the properties and
clinical evidence in more detail) and additional infor-
mation from targeted internet searches and expert
advice if necessary. Any disagreements were resolved by
discussion.
For the included B-I-D combinations, data were col-
lected on: the type of the biomarker used as predictive,
whether it selected a subgroup of patients based on efﬁ-
cacy or toxicity, therapeutic area, marketing status, date
of licensing decision, date of inclusion of the biomarker
in the indication or contraindication and on orphan
designation (granted to drugs intended for the treat-
ment of a life-threatening or chronically debilitating
condition which is either affecting no more than 5 in
10 000 people in the European Union or when the
revenue is unlikely to cover the investment in drug
development21). To provide a context for our review, we
have also collected data on the total number of drugs
licensed each year with and without an orphan
designation.
RESULTS
Across the 18-year period (1995–2012), we identiﬁed 49
B-I-D combinations, including 37 biomarkers and 41 dif-
ferent drugs. The details of the review process are
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presented in ﬁgure 1. Most of the drugs were
authorised, the exceptions being
▸ Gemtuzumab ozogamicin (refused);
▸ Zeldoronic acid (pending);
▸ Imatinib in the indication for aggressive systemic mas-
tocytosis (withdrawn);
▸ Amprenavir (withdrawn);
▸ Nelﬁnavir (withdrawn).
The number of new B-I-D combinations considered by
the EMA each year has increased overall from 0 to 1/
year in the late 1990s, to a maximum of 7 in each of
2011 and 2012 as shown in ﬁgure 2. This was, however,
not a steady increase, as the number of B-I-D combina-
tions considered by the EMA showed a ﬂuctuation
between 2000 and 2006, a decrease between 2006 and
2010, followed by an increase in the number in 2011
and 2012. A predictive biomarker was included in the
indication or contraindication at the time when the
drug was ﬁrst licensed for 35 drugs (for one (capecita-
bine), the date of inclusion of the biomarker was
unclear from the documentation; for the remaining
drugs, the time from the initial licensing decision to the
inclusion of a predictive biomarker ranged from 1 to
10 years). The proportion of ﬁrst licensing decisions of
all new drugs that included a predictive biomarker
increased over time and was close to 10% in 2003, 2004,
2005, 2011 and 2012 (ﬁgure 3).
Six drugs associated with a predictive biomarker had an
orphan designation at the time of licensing; however, for
two drugs, it was removed at the end of exclusivity period
(details reported in table 1). One of the six drugs (imati-
nib) was associated with ﬁve different predictive biomar-
kers in ﬁve different indications (ﬁgure 4).
The identiﬁed predictive biomarkers were all molecu-
lar. Thirty-three biomarkers were used to predict treat-
ment efﬁcacy (details reported in table 1) and only four
to predict toxicity (table 2).
Most of the biomarkers were included in indications
and contraindications of cancer treatments (26 B-I-D
combinations) and viral diseases, mainly HIV (17 B-I-D
combinations). The remaining biomarkers were used to
stratify metabolic and blood disorders (cystic ﬁbrosis,
hyperlipoproteinaemia type I and methemoglobinae-
mia) and appeared in the past 2 years (ﬁgure 2).
DISCUSSION
Stratiﬁed medicine is promoted as key to the future of
medicine, and is currently one of the most active areas
of clinical research. To our knowledge, this review pro-
vides the ﬁrst indication of the number and nature of
predictive biomarkers included in licensing in Europe
based on the drug indications and contraindications on
the EMA website. Forty-nine B-I-D combinations were
identiﬁed. All identiﬁed biomarkers were molecular.
The identiﬁed B-I-D combinations were mainly used in
cancer and HIV treatment, with only ﬁve used in other
disease areas.
It is likely that the 49 identiﬁed B-I-D combinations
from the EMA database do not represent a complete list
of the predictive biomarkers used in practice as some
predictive biomarkers could have been considered by
national regulatory agencies, particularly for drugs con-
sidered before EMA was established in 1995. Also, EMA
licensing is not compulsory for some disease areas, such
as mental health. However, a number of drugs with indi-
cations in depression of schizophrenia have been consid-
ered by the EMA. Therefore, we believe that although
our approach might not provide a complete list of all
predictive biomarkers used in Europe, relatively few are
likely to have been omitted, particularly from recent
years.19 The fact that some of the identiﬁed B-I-D combi-
nations included biomarkers introduced to an indication
of an already licensed drug suggests that at least to some
extent we have captured stratiﬁcation occurring after the
Figure 1 Flow diagram for the systematic review of
predictive biomarkers in the European Medicines Agency
licensing. B-I-D, biomarker–indication–drug; ICD, International
Classification of Diseases.
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initial licensing of a drug. However, the actual extent to
which this takes place in clinical practice is difﬁcult to
evaluate.
Several types of biomarkers were excluded. We did not
include biomarkers used for dose adjustments as they do
not directly predict efﬁcacy or toxicity (although
inappropriate dose adjustment could limit the treatment
efﬁcacy or cause adverse events).22 We also investigated
only biomarkers associated with drug treatments. Other
biomarkers may be used in practice with non-drug treat-
ments (eg, radiotherapy).
The deﬁnition of a predictive biomarker can be difﬁ-
cult to apply, as over time predictive biomarkers may
become part of a redeﬁnition of the disease or subtype
of disease23 and be classed as diagnostic tests. In our
evaluation, we excluded diagnostic biomarkers (eg,
factor IX deﬁciency, or genetic testing for familial lipo-
protein lipase deﬁciency) and biomarkers used to iden-
tify an established subtype of a disease (mainly ST
segment elevation and non-ST segment elevation myo-
cardial infarction).
The spectrum of diseases where predictive biomarkers
have been successfully developed is relatively narrow.
This suggests a possible need for more research in other
clinical areas. Also, the vast majority of the B-I-D combi-
nations were associated with treatment efﬁcacy and only
four with toxicity. As adverse events associated with some
treatments could be potentially serious and the possibil-
ity to screen out patients at high risk prior to the start of
the treatment would be beneﬁcial. A proportion of the
drugs with an associated predictive biomarker identiﬁed
in our review had an orphan designation. This seems
surprising, as convincing evidence to support the use of
a drug in a subgroup of patients with a rare condition
might be difﬁcult to obtain, due to the small numbers
of patients available to test the hypotheses.
It is difﬁcult to provide accurate estimates of the extent
of research into potential predictive biomarkers; however,
it has been suggested in 2011 that the number of publica-
tions on different biomarkers (not only predictive) was
around 15 000.10 Another paper published in 2009, which
reviewed genetic markers evaluated as potential predictors
Figure 2 Number of new
biomarker–indication–drug (B-I-D)
combinations considered each
year by disease area (includes
biomarkers added after the drug
was initially licensed).
Figure 3 New drugs authorised
each year with and without a
predictive biomarker in the
indication or contraindication
(excludes biomarkers added after
the drug was initially licensed).
4 Malottki K, Biswas M, Deeks JJ, et al. BMJ Open 2014;4:e004188. doi:10.1136/bmjopen-2013-004188
Open Access
 group.bmj.com on March 31, 2014 - Published by bmjopen.bmj.comDownloaded from 
Table 1 Biomarkers predictive of efficacy identified in the review of European Medicines Agency licensing
Biomarker Indication Drug
ALK gene rearrangement Carcinoma, non-small-cell lung Crizotinib (Xalkori)
BRAF V600 mutation Melanoma Vemurafenib (Zelboraf)
CCR5 tropism HIV infections Maraviroc (Celsentri)
CD-33 expression* Leukaemia, myeloid, acute Gemtuzumab ozogamicin (Mylotarg)†
EGFR expression Colorectal neoplasms Cetuximab (Erbitux)
EGFR expression Carcinoma, non-small-cell lung Erlotinib (Tarceva)
EGFR mutation Carcinoma, non-small-cell lung Erlotinib (Tarceva)
EGFR mutation Carcinoma, non-small-cell lung Gefitinib (Iressa)
EpCAM expression Cancer ascites Catumaxomab (Removab)
FIP1L1-PDGFR
rearrangement
Hypereosinophilic syndrome Imatinib (Glivec)‡
G551D mutation in the CFTR
gene
Cystic fibrosis Ivacaftor (Kalydeco)†
Genotype 1 HCV Hepatitis C, chronic Boceprevir (Victrelis)
Genotype 1 HCV Hepatitis C Telaprevir (Incivo)
HER2 expression Breast neoplasms Lapatinib (Tyverb)
HER2 expression Breast neoplasms Trastuzumab (Herceptin)
HER2 expression Stomach neoplasms Trastuzumab (Herceptin)
HER2 expression Breast neoplasms Everolimus (Afinitor)
HER2 expression§ Breast neoplasms Pertuzumab (Perjeta)
Hormone dependency Prostatic neoplasms Degarelix (Firmagon)
Hormone receptor
expression§
Breast neoplasms Zoledronic acid (Zometa)
Hormone receptor expression Breast neoplasms Everolimus (Afinitor)
Kit (CD 117) expression Gastrointestinal stromal tumours Imatinib (Glivec)‡
Kit (D816V) mutation¶ Aggressive systemic mastocytosis Imatinib (Glivec)‡
KRAS mutation Colorectal neoplasms Cetuximab (Erbitux)
KRAS mutation Colorectal neoplasms Panitumumab (Vectibix)
LPL protein detectable Hyperlipoproteinaemia type I Alipogene tiparvovec (Glybera)†
Oestrogen receptor expression Breast neoplasms Fulvestrant (Faslodex)
Oestrogen receptor expression Breast neoplasms Toremifene (Fareston)
PDGFR gene rearrangements Myelodysplastic-myeloproliferative diseases Imatinib (Glivec)‡
Philadelphia chromosome Precursor cell lymphoblastic
leukaemia-lymphoma
Dasatinib (Sprycel)†
Philadelphia chromosome Precursor Cell lymphoblastic
leukaemia-lymphoma
Imatinib (Glivec)‡
t(15; 17) translocation Leukaemia, promyelocytic, acute Arsenic trioxide (Trisenox)‡
Viral resistance mutations¶ HIV infections Amprenavir (Agenerase)
Viral resistance mutations HIV infections Atazanavir sulfate (Reyataz)
Viral resistance mutations HIV infections Darunavir (Prezista)
Viral resistance mutations HIV infections Efavirenz/emtricitabine/tenofovir disoproxil
(Atripla)
Viral resistance mutations HIV infections Emtricitabine (Emtriva)
Viral resistance mutations HIV infections Emtricitabine/rilpivirine/tenofovir disoproxil
(Eviplera)
Viral resistance mutations HIV infections Enfuvirtide (Fuzeon)
Viral resistance mutations HIV infections Fosamprenavir calcium (Telzir)
Viral resistance mutations HIV infections Lopinavir/ritonavir (Kaletra)
Viral resistance mutations¶ HIV infections Nelfinavir (Viracept)
Viral resistance mutations HIV infections Rilpivirine hydrochloride (Edurant)
Viral resistance mutations HIV infections Tenofovir disoproxil fumarate (Viread)
Viral resistance mutations HIV infections Tipranavir (Aptivus)
*Refused.
†Drug designated an orphan medicine.
‡Orphan designation has been removed at the end of exclusivity period.
§Pending.
¶Withdrawn.
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of response to treatment, found that 541 different genes
were investigated as potential predictive biomarkers in
1668 papers.11 It can be reasonably expected that this
number largely increased since these papers were pub-
lished. Our review shows that few predictive biomarkers
have been included in licensing relative to this large body
of literature documenting numerous potential predictive
biomarkers. Therefore, in spite of the substantial invest-
ment in research, the promise of stratiﬁed medicine is not
yet being realised to a large extent. The reasons for this
might include poor translation of ﬁndings of laboratory
studies into clinical context, or the failure to identify
effective predictive biomarkers and treatments. Even
though it is becoming easier and cheaper to gather huge
sets of genomic data, its interpretation is challenging,
which can potentially hinder translational research.
Recognising this, initiatives have been undertaken in the
USA (National Institutes of Health and the Food and
Drug Administration) and the UK (Medical Research
Council) to promote the translation of basic research into
clinical practice.12 In addition, the availability of datasets
such as the Cancer Cell Line Encyclopaedia and a similar
UK initiative might contribute to the faster progress of
stratiﬁed medicine.24 25 The relatively small number of
predictive biomarkers identiﬁed in licensing might also
indicate the need for more sound methodological stan-
dards for biomarker discovery and development.26
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